Epstein Secrets

anagement did a poor job communicating it to the analysts! Thank you Boris From: on hershkovitz [mailto Sent: Monday, June 15, 2015 10:35 PM To: Boris Nikolic Cc: Daniel Malek; Nickolay Voronin Subject: Re: FW: AAVL - we see that news came out after mkt close. Hi Boris, Nick believes market wanted to see a

very confused re thickening of the retina. Finally, I really think that the management did a poor job communicating it to the analysts! Thank you Boris From: on hershkovitz [mailto Sent: Monday, June 15, 2015 10:35 PM To: Boris Nikolic Cc: Daniel Malek; Nickolay Voronin Subject: Re: FW: AAVL - w

From: Boris Nikolic C To: "jeevacationg,gmail.com" <jeevacation@gmai

for maintaining their stable VA while the AVA-101 treated arm was able to maintain (and even improve ) the baseline levels of visual acuity. -More AVA-101 treated subjects improved or maintained stable vision (>-5 letters) with a low number (≤2) of rescue treatments. Specifically, 23.8 percent (treated

does show, in my opinion, is that the "rescue treatment" administrated to the placebo arm was sub-optimal for maintaining their stable VA while the AVA-101 treated arm was able to maintain (and even improve ) the baseline levels of visual acuity. -More AVA-101 treated subjects improved or maintained st

From: Boris Nikolic To: Jeffrey Epstein <jeevacation(ggmail.com> Subject: FW: AAVL Date: Fri, 14 Aug 2015 15:01:38 +0000 Attachments: disclaim.txt Inline-Images: ima

at on it. The price per share is less what they have on a bank Sent from my Windows Phone Fro Sent. 1.111P m To: Boris Nikolic Subject: AAVL Hi Boris, AAVL is trading pre-market at 12.05x12.15 on —100k volume. Analysts price targets were generally halved (see BBG grab below) on news that manageme

From: Boris Nikolic To: Jeffrey Epstein <jeevacation(ggmail.com> Sub

uncing post-mkt yday plans to scrap a planned Phase 2b trial and instead initiate added preclinical studies to investigate optimal dose, delivery of AVA-101 and AVA-201 in wet age-related macular degeneration (wet AMD). * "Investors need a clear path forward" before getting back in AAVL, Cowen analyst

yet. Will keep and seat on it. The price per share is less what they have on a bank Sent from my Windows Phone From Sent: 8/=FD14/2015 16:30 To: Boris Nikolic Subject: AAVL<=span> Hi Boris, AAVL is trading pre-market at 12.05x12.15 on —100k v=lume. Analysts price targets were generally halved (see BBG gr

ce per share is less what they have on a bank Sent from my Windows Phone From Sent: 8/=FD14/2015 16:30 To: Boris Nikolic Subject: AAVL<=span> Hi Boris, AAVL is trading pre-market at 12.05x12.15 on —100k v=lume. Analysts price targets were generally halved (see BBG grab below) on=news that manageme

From: Boris Nikolic Sent: Friday, August 14, 2015 3:02 PM To: Jef

uncing post-mkt yday plans =o scrap a planned Phase 2b trial and instead initiate added preclinical st=dies to investigate optimal dose, delivery of AVA-101 and AVA-201 in wet age-related macular degeneration (wet AMD). • "Investors need a clear path forward=94 before getting back in AAVL, Cowen analys